ArticleOncotarget2018
The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma.
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- Review
- Tumor-infiltrating B cells participate in shaping the immunosuppressive microenvironment in solid tumors.International journal of cancer · 2026Review
- Immune cell profiling of peripheral blood in long-term testicular germ cell tumor survivors.Frontiers in immunology · 2025Article
- Review
- B-cell performance in chemotherapy: Unravelling the mystery of B-cell therapeutic potential.Clinical and translational medicine · 2024Review
- ADA/CD26 axis increases intra-tumor PD-1Oncoimmunology · 2024Article
- Direct immunoactivation by chemotherapeutic drugs in cancer treatment.Advanced therapeutics · 2023Article
- Low Pretreatment CD4International journal of molecular sciences · 2023Article
- Role of chemotherapeutic drugs in immunomodulation of cancer.Current research in immunology · 2023Review
- Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.Frontiers in immunology · 2023Review
- Mechanisms of induction of regulatory B cells in the tumour microenvironment and their contribution to immunosuppression and pro-tumour responses.Clinical and experimental immunology · 2022Review
- Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities.Nature reviews. Cancer · 2022Review
- The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.Frontiers in immunology · 2022Review
- Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma.Frontiers in oncology · 2022Review
- Review
- The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment.Journal of clinical medicine · 2020Review
- Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73.Purinergic signalling · 2020Article
- Adenosine-producing regulatory B cells in head and neck cancer.Cancer immunology, immunotherapy : CII · 2020Article
- Adenosine production in mesenchymal stromal cells in relation to their developmental status.HNO · 2020Article
- Treatment-induced changes of lymphocyte subsets in patients with adenoid cystic carcinoma of the head and neck.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
introductionHead and neck squamous cell carcinoma (HNSCC) strongly suppresses the immune system, resulting in increased metastasis and recurrent disease. Chemotherapy is part of the multimodal treatment but may further immunosuppression. Recently, we demonstrated that regulatory B cells (Breg), defined as CD19
resultsIn HNSCC patients, Breg were diminished in absolute number and frequency after chemotherapy (paired samples). Chemotherapeutic drugs had variable effects; while platinum-based chemotherapy decreased the expression of CD39, methotrexate led to a functional increase in CD39 expression and increased production of immunosuppressive ADO. These findings were confirmed in a second patient cohort. Surface expression of CD39 correlated strongly with the production of ADO as measured by mass spectrometry.
conclusionsPlatinum-based anti-tumor-therapy reduces the number of adenosine-producing B cells and, consequently, potential immunosuppression within the tumor environment. Breg function in terms of ADO production and their potential capacity to suppress CD4
methodsMononuclear cells were collected prospectively from HNSCC patients before and after chemotherapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.